Home / Themes / MedTech Long '25: Wearable Health
MedTech Long '25: Wearable Health (view performance)
Last updated
Theme thesis · 1 upload · 5/5 sections · Tickers 6 with notes · 11 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsWearable Health benefits from expanding reimbursement for chronic disease monitoring, driven by policy favoring preventative care and AI-enhanced platforms. Whi
Thesis
Wearable Health benefits from expanding reimbursement for chronic disease monitoring, driven by policy favoring preventative care and AI-enhanced platforms. While GLP-1 substitution and slow reimbursement for novel categories pose risks, structural tailwinds and technological advancements make the bull case more compelling.
Bull case
CMS and Medicare Advantage are expanding reimbursement for remote monitoring and Continuous Glucose Monitoring (CGM) technologies, broadening market access and utilization.
Policy tailwinds, particularly under a potential Trump 2.0 administration, favor preventative technology and continuous monitoring, aligning with cost-saving and chronic disease prevention priorities.
AI-enhanced wearable platforms are seeing adoption gains, with AI-driven monitoring receiving growing clinical support and provider integration interest, improving diagnostic and proactive care capabilities.
Bear case
Wearables face GLP-1 substitution risk: As obesity and diabetes rates decline via GLP-1s, demand for CGMs and related monitoring may moderate, impacting a key market segment.
Reimbursement processes for newer wearable categories (e.g., neuromuscular) could lag product innovation, leading to slow and fragmented payer adoption despite policy momentum.
Valuation multiples for many wearable health names remain high, making them vulnerable to macro-economic shifts, interest rate changes, or any disappointments in utilization or growth.
Overview
Hiring Trend Watchpoints
High-performing operators in the Wearable Health theme are expected to show robust hiring in specialized technical and clinical roles. Key areas include AI/Machine Learning engineers and data scientists to develop predictive analytics and enhance device intelligence. Software developers, particularly those with expertise in mobile health, cloud infrastructure, and data interoperability, will be crucial for platform development and EHR integration. Regulatory affairs specialists and clinical trial managers are essential to navigate evolving FDA guidelines and secure clinical validation. Additionally, cybersecurity experts are increasingly vital to ensure the privacy and security of sensitive health data. UX/UI designers focused on patient adherence and ease of use will also be in demand. Watch for increased hiring in commercial and sales roles as companies expand market penetration. A slowdown in R&D or clinical roles could signal a pause in innovation or market saturation, while a significant increase in data privacy/security roles would indicate growing regulatory pressure and focus on data integrity.
Forum Watchlist
- Reddit Community — r/diabetesHigh
Patient sentiment, user experience, and real-world effectiveness of CGMs and diabetes management wearables, including discussions around GLP-1 drug interactions and new device comparisons.
- Reddit Community — r/cardiologyHigh
Discussions around wearable ECGs, remote cardiac monitoring, arrhythmia detection, and patient experiences with devices like Zio XT/AT.
- Reddit Community — r/epilepsyMedium
Emerging wearable solutions for seizure detection, monitoring, and patient quality of life improvements.
- Reddit Community — r/wearablesMedium
General trends, new product announcements, user reviews, and comparisons of medical-grade vs. consumer health wearables.
- Reddit Community — r/digitalhealthMedium
Broader discussions on digital health policy, reimbursement, AI integration in health tech, and interoperability challenges for wearable data.
Industry Publications
- MedTech World Magazine (medtechworld.com) — Provides informed analysis, expert insights, and covers healthcare technology, regulation, investment, and implementation from an industry-led perspective.
- MedTech Intelligence (medtechintelligence.com) — Offers business analysis, technology trends, regulatory updates, and market insights specific to the medical device industry.
- MobiHealthNews (mobihealthnews.com) — Focuses specifically on digital health, mobile health, and wearable technology news, trends, and policy.
- Fierce Healthcare (fiercehealthcare.com) — Covers healthcare industry news, policy, and technology, including significant developments in remote patient monitoring and digital health.
- STAT News (statnews.com) — Provides in-depth reporting on health, medicine, and life sciences, often featuring investigative pieces on medtech innovation and regulation.
- Endpoints News (endpts.com) — Offers breaking news and analysis on biotech, pharma, and medtech, with a strong focus on clinical trials and regulatory milestones.
- Medical Device and Diagnostic Industry (MD+DI) (mddionline.com) — Covers medical device design, manufacturing, regulation, and market trends, including wearable device development.
- Health Affairs (healthaffairs.org) — A leading journal for health policy thought and research, crucial for understanding reimbursement and regulatory shifts.
Second Order Trends
Several second-order trends are shaping the Wearable Health theme. Firstly, the increasing integration of **AI and predictive analytics** is transforming wearables from mere data collectors into tools for proactive and personalized preventive care, analyzing patterns to anticipate health issues. This is moving beyond simple tracking to offer actionable insights and early warning systems. Secondly, there's a growing **convergence of consumer and medical devices**, with high-end consumer wearables increasingly seeking FDA clearances, blurring the lines between 'wellness' and 'medical' devices and raising expectations for accuracy and clinical validation. Thirdly, **data interoperability and EHR integration** are becoming critical, as healthcare providers demand seamless integration of wearable data into electronic health records for holistic patient management and clinical decision support. Fourthly, **cybersecurity and data governance** are gaining heightened focus due to regulatory pressures and the sensitive nature of health data, requiring robust solutions to ensure privacy and security. Lastly, the **impact of GLP-1 medications** is evolving; beyond simple substitution risk for CGMs, there's a nuanced understanding emerging of how these drugs might redefine the role of continuous monitoring for pre-diabetes, metabolic health optimization, or monitoring GLP-1 efficacy, rather than just replacing it.
Search Keywords Brand Product
- Continuous Glucose Monitoring
- CGM
- Zio XT
- Zio AT
- MyoPro
- Remote Patient Monitoring
- RPM
- Remote Therapeutic Monitoring
- RTM
- wearable health devices
- sensor-based platforms
- digital health platforms
- smart medical devices
- AI-powered diagnostics
- smart health patches
- continuous vital sign monitoring
- wearable ECG
- wearable blood pressure monitor
Search Keywords Policy Regulatory
- Medicare Advantage reimbursement
- CMS remote monitoring
- CPT codes wearables
- HCPCS wearable devices
- FDA General Wellness Policy
- FDA Clinical Decision Support Software
- digital health regulation
- preventative care policy
- FDA breakthrough device designation wearables
- health data privacy wearables
Search Keywords Event Phrases
- FDA wearable approval
- MedTech conference
- Heart Rhythm Society meeting
- American Diabetes Association Scientific Sessions
- CES health tech
- HIMSS wearable tech
Google Trend Product Category Intent
• continuous glucose monitor
• wearable heart monitor
• remote physical therapy device
• smart health tracker
• medical wearable
• ECG wearable
• blood pressure wearable
• sleep tracking medical device
• stress monitoring wearable
• wearable fall detection
Google Trend Consumer Intent
• preventative health tech
• at-home medical monitoring
• chronic disease management wearables
• health data sharing
• digital health solutions
• wearable for seniors
• personal health dashboard
• wearable health benefits
Google Trend Macro Policy Terms
• Medicare Advantage benefits
• digital health policy
• FDA wearable guidelines
• remote monitoring reimbursement
• GLP-1 impact on wearables
• health data security regulations
Top datasets to track
1. Medicare Advantage Encounter Data Type: Government/Claims Data · Provider: CMS, Leavitt Partners Cadence: Quarterly Why it matters: Measures real-world utilization growth for DXCM, IRTC under expanded MA coverage and overall adoption of RPM/CGM. Suggested query: Medicare Advantage RPM CGM claims data Confidence: High
2. Wearable Health Device Shipments and Prescriptions Type: Market Research/Sales Data · Provider: IQVIA DeviceTrack, Bloomberg Supply Chain, IDC, Grand View Research Cadence: Monthly/Quarterly Why it matters: Tracks demand trends for wearable platforms across diabetes, cardiac, and neuro use, and overall market growth. Suggested query: wearable device shipments medical Confidence: High
3. CMS Physician Fee Schedule Updates Type: Government/Policy Data · Provider: CMS, AMA CPT Panel, industry trackers Cadence: Quarterly/Annually Why it matters: Captures policy progress for reimbursable wearable services across conditions, directly impacting revenue potential. Suggested query: CMS RPM CPT codes 2026 Confidence: High
4. FDA Device Approvals Database Type: Regulatory Data · Provider: FDA Cadence: Continuous/Monthly Why it matters: Indicates regulatory progress and market entry for new, clinically validated wearable technologies, especially those moving beyond 'general wellness'. Suggested query: FDA wearable medical device approvals Confidence: High
5. GLP-1 Prescription Volume Data Type: Pharmaceutical Sales Data · Provider: IQVIA, pharmaceutical companies Cadence: Quarterly Why it matters: Monitors the potential substitution risk for CGM demand, especially for Type 2 diabetes management, as GLP-1 adoption grows. Suggested query: GLP-1 prescription trends diabetes Confidence: Medium
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Medicare Advantage CGM and RPM claims volume | Quarterly | Measures real-world utilization growth for DXCM, IRTC under expanded MA coverage. | Google_Sheets |
| Device prescriptions and shipments for wearable health | Monthly | Tracks demand trends for wearable platforms across diabetes, cardiac, and neuro use. | Google_Sheets |
| Remote monitoring reimbursement updates (CPT, HCPCS) | Quarterly | Captures policy progress for reimbursable wearable services across conditions. | Google_Sheets |
Upcoming Catalysts
| Catalyst | Estimated Timing | Estimated Date Start | Estimated Date End | Why It Matters | Ticker Or Theme Specific | Source Types | Contributing Tickers | Mention Count | Base Score | Source Weight | Specificity Weight | Macro Bridge | Macro Bridge Multiplier | Theme Score | Date Aggregated | Manual Override | Bridge Mention Count | Theme Base Score | Theme Importance Score | Catalyst Source | Catalyst ID | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicare reimbursement expansion for continuous glucose monitoring (CGM) for Type 2 non-insulin users in the US. | could happen in the fall | 2026-09-01 | 2026-11-30 | This represents a multibillion-dollar opportunity, unlocking coverage for approximately 10 million Medicare beneficiaries and accelerating commercial insurance adoption, which is expected to significantly boost CGM sales. | Ticker | ABT (ticker) | ABT_ba778762 | 2026-07-16 | earnings_transcript | ||||||||||||||
| International rollout of Libre Duo, the world's first dual glucose ketone monitoring sensor. | in the fall | 2026-09-01 | 2026-11-30 | The introduction of this innovative new technology internationally is expected to contribute to the growth and leadership of Abbott's diabetes care business. | Ticker | ABT (ticker) | ABT_6009f906 | 2026-07-16 | earnings_transcript | ||||||||||||||
| CMS decision on coverage expansion for Type 2 non-insulin diabetes patients, following the submission of Connect trial data. | before the end of this year | 2026-08-07 | 2026-12-31 | This decision has the potential to significantly expand the addressable market for Dexcom CGM in the US, impacting 25 million Type 2 non-insulin customers. | Ticker | DXCM (ticker) | DXCM_e0606eaf | 2026-07-30 | earnings_transcript | ||||||||||||||
| FDA clearance for Mobi Tubeless, enabling its commercial launch. | second half of the year | 2026-07-01 | 2026-12-31 | Regulatory approval is necessary to launch this significant new product, which is Tandem's first patch pump and the world's first with extended wear technology, potentially impacting market share and revenue. | Ticker | TNDM (ticker) | TNDM_82e30c2b | 2026-02-20 | earnings_transcript | ||||||||||||||
| Commercial launch of Mobi Tubeless, a novel infusion site option for the Mobi pump that transforms it into a tubeless patch device. | second half of the year | 2026-07-01 | 2026-12-31 | Introduces a new form factor and technology, potentially expanding Tandem's addressable market and competitive position against patch pump competitors, though not included in 2026 revenue guidance. | Ticker | TNDM (ticker) | TNDM_a7005c10 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Initiation of a pivotal trial for Tandem's fully closed-loop automated insulin delivery algorithm. | later this year | 2026-07-01 | 2026-12-31 | A crucial step towards developing a next-generation AID system, aiming for FDA filing in 2027, which is vital for maintaining Tandem's leadership in AID innovation. | Ticker | TNDM (ticker) | TNDM_8eea9c45 | 2026-02-20 | earnings_transcript | ||||||||||||||
| Pharmaceutical companies (e.g., Novo Nordisk, Eli Lilly) will release Q3 and Q4 2026 earnings, providing updated prescription volume data and sales figures for GLP-1 medications, alongside anticipated FDA approvals and launches of new GLP-1 drugs like Novo Nordisk's CagriSema (late 2026) and Boehringer Ingelheim's survodutide (H1 2027). | October-November 2026 (Q3 earnings), Q1 2027 (Q4 earnings and new drug launches). | 2026-10-01 | 2027-03-31 | The continued rapid adoption and expansion of GLP-1 therapies, particularly oral formulations and new market entrants, pose a significant substitution risk for continuous glucose monitoring (CGM) demand, directly impacting companies like Dexcom (DXCM). | Theme | theme_composer | DXCM | 1 | 0.0008 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 0.1149 | 2026-08-06 | False | 1 | 0.0075 | 1.1014 | Theme composer | |||
| FDA approval for the new Amulet 360 left atrial appendage device. | potential to be able to get this approved by year end | 2026-10-01 | 2026-12-31 | This approval enables a significant relaunch of a superior product in the $2 billion LAA closure market, positioning Abbott for substantial market share capture in the electrophysiology business. | Ticker | ABT (ticker) | ABT_30e24e43 | 2026-07-16 | earnings_transcript | ||||||||||||||
| Dexcom expects to convert nearly 50% of its US customer base to the G7 15-day system. | by year end | 2026-10-01 | 2026-12-31 | This conversion is translating into stronger customer satisfaction and is expected to contribute to improved gross margins. | Ticker | DXCM (ticker) | DXCM_b887655c | 2026-07-30 | earnings_transcript | ||||||||||||||
| Start of pivotal trial for MiniMed's next-generation extended wear sensor in the U.S. | October | 2026-10-01 | 2026-10-31 | This program demonstrates continued innovation beyond current products, aiming to improve user experience, strengthen competitive position, and be accretive to margins through longer wear duration. | Ticker | MMED (ticker) | MMED_f53c1ad9 | 2026-09-01 | earnings_transcript | ||||||||||||||
| Transition to direct commercial operations in additional key European markets, following the playbook from initial transitions. | in the fourth quarter | 2026-10-01 | 2026-12-31 | Expected to improve price and margins (ASP premiums at least 30% higher) and deepen relationships, but also involves an anticipated $15 million headwind from distributor destocking and inventory buybacks for 2026. | Ticker | TNDM (ticker) | TNDM_709c0ea7 | 2026-02-20 | earnings_transcript | ||||||||||||||
| The Centers for Medicare & Medicaid Services (CMS) will publish the Calendar Year (CY) 2027 Physician Fee Schedule (PFS) final rule, which is expected to finalize significant proposed changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. | Final rule publication in November 2026; effective January 1, 2027. | 2026-11-01 | 2027-01-01 | This catalyst is critical as the proposed changes, including requiring RPM/RTM services to be furnished by direct employees and potentially consolidating CPT codes, could fundamentally alter the operational and financial models for companies providing remote monitoring solutions. It directly impacts the reimbursement landscape for wearable health devices. | Theme | theme_composer | DXCM, IRTC, MYO | 3 | 0.001 | 1.18 | 1.0 | 1.0 | 0.1129 | 2026-08-06 | False | 1 | 0.4085 | 48.1984 | Theme composer | ||||
| CMS to publish the CY 2027 Physician Fee Schedule final rule, finalizing changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. | Final rule publication in November 2026; effective January 1, 2027. | 2026-11-01 | 2027-01-01 | This rule could significantly alter the operational and financial models for companies providing remote monitoring solutions, directly impacting the reimbursement landscape for wearable health devices including Dexcom's offerings. | Theme | DXCM (ticker) | DXCM_80554779 | 2026-07-30 | earnings_transcript | ||||||||||||||
| European commercial launch of MiniMed Flex. | November of this year | 2026-11-01 | 2026-11-30 | This launch follows CE Mark approval and is expected to drive strong growth in international markets by expanding reach into new patients and increasing competitive conversions. | Ticker | MMED (ticker) | MMED_99ed2845 | 2026-09-01 | earnings_transcript | ||||||||||||||
| The Centers for Medicare & Medicaid Services (CMS) is introducing a new "Software as a Medical Service" payment framework for algorithm-driven technologies in its Calendar Year (CY) 2027 payment rules, alongside ongoing updates and clarifications from the FDA regarding its AI framework and digital health guidance. | January 1, 2027 (CMS framework effective date), ongoing throughout 2026-2027 (FDA guidance updates). | 2027-01-01 | 2027-12-31 | This catalyst provides a clearer regulatory and reimbursement pathway for AI-enhanced wearable platforms, potentially accelerating adoption and market entry for innovative diagnostic and monitoring solutions, benefiting companies integrating AI into their devices. | Theme | theme_composer | IRTC, MYO, DXCM | 3 | 0.0011 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 0.1617 | 2026-08-06 | False | 1 | 0.4085 | 59.8624 | Theme composer | |||
| Regulatory filing for Insulet's fully closed-loop system for Type 2 diabetes. | supporting a regulatory filing in 2027 | 2027-01-01 | 2027-12-31 | Successful regulatory filing is a prerequisite for commercial launch, enabling Insulet to access the vast and underpenetrated Type 2 diabetes market with a highly differentiated product, impacting future revenue and valuation. | Ticker | PODD (ticker) | PODD_5dda514d | 2026-02-18 | earnings_transcript | ||||||||||||||
| Commercial launch of Insulet's next-generation Omnipod 6 system. | accelerate our innovation cycle as we prepare for launch in 2027 | 2027-01-01 | 2027-12-31 | This next-gen platform is designed to offer improved connectivity, flexibility, and personalized automation, crucial for maintaining competitive leadership and driving future revenue growth and investor sentiment. | Ticker | PODD (ticker) | PODD_93a0b76a | 2026-02-18 | earnings_transcript | ||||||||||||||
| Resumption of formal full-year financial guidance. | early 2027 | 2027-01-01 | 2027-03-31 | This will provide investors with clarity on management's expectations for the company's performance after the business assessment, impacting investor confidence and valuation. | Ticker | RXST (ticker) | RXST_99260578 | 2026-08-05 | earnings_transcript | ||||||||||||||
| The Heart Rhythm Society's annual meeting, Heart Rhythm 2027, will gather the global electrophysiology community to discuss groundbreaking science, clinical education, and innovations in cardiac pacing and electrophysiology. | May 13-16, 2027. | 2027-05-13 | 2027-05-16 | This conference is crucial for companies in cardiac monitoring, as it showcases new research, product developments, and discussions on digital health and innovation relevant to wearable heart monitors and diagnostic devices. | Theme | theme_composer | IRTC | 1 | 0.0001 | 1.18 | 1.05 | Conference/Council | 1.2 | 0.0133 | 2026-08-06 | False | 1 | 0.0009 | 0.1392 | Theme composer | |||
| Full U.S. launch of MiniMed Fit, a patch pump. | by summer next year | 2027-06-01 | 2027-08-31 | Fit brings MiniMed's differentiated therapy platform to the fastest-growing segment of the insulin pump market, expanding reach into new patients and driving competitive conversions. | Ticker | MMED (ticker) | MMED_21687391 | 2026-09-01 | earnings_transcript | ||||||||||||||
| The 87th American Diabetes Association (ADA) Scientific Sessions will convene, bringing together professionals to share the latest developments in diabetes research, prevention, and care. | June 18-21, 2027. | 2027-06-18 | 2027-06-21 | This major conference is a key platform for presenting new clinical data, technological advancements, and policy discussions related to diabetes management, directly impacting companies involved in continuous glucose monitoring and other diabetes-focused wearable health solutions. | Theme | theme_composer | DXCM | 1 | 0.0008 | 1.18 | 1.05 | Regulatory/Policy, Conference/Council | 1.62 | 0.1705 | 2026-08-06 | False | 1 | 0.0075 | 1.5085 | Theme composer | |||
| Commercial launch of Insulet's fully closed-loop system for people with Type 2 diabetes. | a commercial launch in 2028 | 2028-01-01 | 2028-12-31 | This system is designed to make AID accessible to virtually everyone with Type 2 diabetes, significantly expanding the addressable market and driving future growth, potentially solidifying Insulet's leadership in this segment. | Ticker | PODD (ticker) | PODD_fdc63d7d | 2026-02-18 | earnings_transcript | ||||||||||||||
| Insulet's new manufacturing facility in Costa Rica becomes operational. | expected to be operational in 2029 | 2029-01-01 | 2029-12-31 | This investment in capacity and automation is critical for supporting long-term industry-leading growth and achieving continued margin expansion, impacting profitability and valuation. | Ticker | PODD (ticker) | PODD_55d4bc0d | 2026-02-18 | earnings_transcript |
NotesEarnings Summary
| Date | Type | Comment | Detail | Sentiment | Tickers |
|---|---|---|---|---|---|
| 2026-08-06 | Ticker Analysis | The RxSight (RXST) transcript, focused on intraocular lenses for cataract surgery, has no direct relevance to the "MedTech Long '25: Wearable Health" theme. RXST's business model does not involve wearable or sensor-based platforms for chronic disease monitoring, mobility restoration, or cardiac/diabetes management, which are the core components of this theme. | Earnings Summary | Neutral | RXST |
Constituents
- ABTT2— Abbott Laboratories
- DXCMT3— DexCom, Inc.
- MMEDT3— MiniMed Group, Inc. Common Stock
- PODDT3— Insulet Corp.
- RXSTT3— RxSight, Inc.
- TNDMT3— Tandem Diabetes Care, Inc.
- 294090.KOT3· no notes yet
- 3407.TT3· no notes yet
- 7779.TT3· no notes yet
- BTCYT3· no notes yet
- CHRNT3· no notes yet
- ECORT3· no notes yet
- IRTCT3· no notes yet
- LFWDT3· no notes yet
- MASIT3· no notes yet
- MYOT3· no notes yet
- SENST3· no notes yet